EUCTR2014-003985-25-DE进行中（未招募）1 期
Multi-centre, randomized, double-blind, placebo-controlled, phase II study assessing in two sequential cohorts the safety, efficacy and tolerability of a 15 mg BID and a 30 mg BID doses of SER150TBS in well controlled type II diabetic patients with diabetic nephropathy and albuminuria in stable antidiabetic treatment
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Serodus ASA
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males or females
- •2. Aged 18 to 85 years, inclusively
- •3. Female patient is either post-menopausal (presents at least a 12 month period of amenorrhea in women aged = 55 years and two years in those aged < 55 years, and presents / presented clinical signs of menopause: hot flashes, irregular menstrual periods, vaginal drying, sleep disorders, depression and irritability) or surgically sterilized (hysterectomy or bilateral oophorectomy).
- •4. General good health (ASA class 1 or 2)
- •5. Well controlled type II diabetes diagnosis
- •6. Stable antidiabetic treatment (unchanged during the last 3 months, including intensive insulin therapy)
- •7. Diabetic nephropathy defined either by a positive biopsy or in its absence, by increased urinary albumin excretion in the absence of other renal disease or condition that would explain the albuminuria (for a diabetic patient presenting concomitantly a well-controlled hypertension, a hypertensive nephrosclerosis possibility would not be an exclusion criterion)
- •8. Albuminuria, either micro (ACR 30-300 mg/g) or macro (ACR >300 mg/g)
- •9. ALAT, or ASAT values not exceeding 1.5x ULN
- •10. ALP, PT (or its international normalized ratio (INR)) and bilirubin within normal values
- •11. eGFR equal or above 30 ml/min (CKD-Epi-formula)
- •12. Glycated haemoglobin (HbA1c) = 7.5%. A HbA1c value up to 8.5 % is acceptable in well controlled patients (according to the investigator’s opinion), particularly in elderly patients
- •13. Normal blood pressure or well controlled hypertension (maximum 140 mm Hg systolic and 90 mm Hg diastolic)
- •Ethical/Other:
- •14. Patient has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 47
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 47
排除标准
- •1. Recent history or ongoing liver disease, including viral infections (Hepatitis A/B/C/D/E, Coxsackie, or other viral infections of the liver)
- •2. ALAT or, ASAT values exceeding 1.5x ULN
- •3. ALP, PT (or its international normalized ratio (INR)) or bilirubin values exceeding the ULN
- •4. Stroke within the last 3 months
- •5. Systemic infections during the last month
- •6. Severe renal failure (eGFR under 30 ml/min, CKD-Epi-formula)
- •7. Chronic treatment with non-steroidal anti-inflammatory drugs (NSAID) including regular dose aspirin. Low dose aspirin treatment up to 100 mg/d is allowed.
- •8. Any bleeding disorder or acute blood coagulation defect
- •9. A history of gastric ulcers or any other organic lesion susceptible to bleeding
- •10. Subjects who have undergone any kind of surgery in the last 2 weeks before IMP/placebo administration
- •11. Others: allergy to the active substance or any of the excipients of the IMP
- •12. Pregnant or lactating women
- •13. Only for participation in the second cohort: Patients having participated in the first cohort
- •14. Present participation in another clinical study or having participated in a clinical study requiring the administration of an investigational medicine, 6 months prior to enrolment (i.e. no interaction with the previous investigational medicine should be possible)
- •15. History of serious cardiac disease, defined as myocardial infarction within three months of inclusion, congestive heart failure classified by the New York Heart Association as Class III or IV, poorly controlled or unstable angina, electrocardiographic evidence of acute ischemia, or clinically significant cardiac arrhythmias (i.e. the patient should have no symptoms and need no specific treatment, or have an appropriate treatment with successful control)
- •Ethical/Other:
- •16. Subjects committed to an institution by virtue of an order issued either by the judicial or the administrative authorities
- •17. Subjects dependent on the sponsor, investigators, personnel of the trial site or any other individual whose willingness to volunteer may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate
研究者
相似试验
进行中（未招募）
1 期
A clinical trial comparing the efficacy, and safety and tolerability of two disease modifying MS drugs (GTR and Copaxone®) in patients with relapsing remitting multiple sclerosis for 9 months followed by a 15 month GTR treatment part to evaluate efficacy and safety of long-term GTR treatment.EUCTR2011-000888-27-ROSynthon BV796
进行中（未招募）
不适用
A clinical trial comparing the efficacy, and safety and tolerability of two disease modifying MS drugs (GTR and Copaxone) in patients with relapsing remitting multiple sclerosis for 9 months followed by a 15 month GTR treatment part to evaluate efficacy and safety of long-term GTR treatment.Relapsing remitting multiple sclerosisMedDRA version: 14.1Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-000888-27-ITSYNTHON BV750
进行中（未招募）
不适用
A clinical trial comparing the efficacy, and safety and tolerability of two disease modifying MS drugs (GTR and Copaxone®) in patients with relapsing remitting multiple sclerosis for 9 months followed by a 15 month GTR treatment part to evaluate efficacy and safety of long-term GTR treatment.Relapsing remitting multiple sclerosisMedDRA version: 14.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-000888-27-GBSynthon BV750
进行中（未招募）
不适用
A clinical trial comparing the efficacy, and safety and tolerability of two disease modifying MS drugs (GTR and Copaxone®) in patients with relapsing remitting multiple sclerosis for 9 months followed by a 15 month GTR treatment part to evaluate efficacy and safety of long-term GTR treatment.Relapsing remitting multiple sclerosisMedDRA version: 14.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-000888-27-CZSynthon BV750
进行中（未招募）
不适用
A clinical trial comparing the efficacy, and safety and tolerability of two disease modifying MS drugs (GTR and Copaxone®) in patients with relapsing remitting multiple sclerosis for 9 months followed by a 15 month GTR treatment part to evaluate efficacy and safety of long-term GTR treatment.Relapsing remitting multiple sclerosisMedDRA version: 15.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-000888-27-EESynthon BV750